81 Participants Needed

Ribitol for Limb-Girdle Muscular Dystrophy

(Fortify Trial)

Recruiting at 28 trial locations
DS
JK
CG
MB
DL
Overseen ByDoris Leung, MD
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial will test the safety and effectiveness of BBP-418 in patients aged 12 to 60 who have a specific type of muscular dystrophy called LGMD2I/R9. The goal is to see if this new treatment can help improve their condition over several months.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot use ribose or other sugar alcohol supplements, systemic corticosteroids for muscular dystrophy, or be on experimental therapies within 90 days before the screening. It's best to discuss your current medications with the study team.

Is ribitol safe for use in humans?

Ribitol has been tested in animal models and clinical trials in humans without severe side effects, although some gastrointestinal issues like bloating and loose stool were observed at higher doses.12345

What makes the drug Ribitol unique for treating Limb-Girdle Muscular Dystrophy?

Ribitol is unique because it works by increasing the levels of a specific sugar molecule called matriglycan, which is important for muscle function, and it compensates for the decreased function of a mutated protein in the disease. Unlike other treatments, it is a simple sugar alcohol that can be administered orally and has shown to improve muscle function and lifespan in animal models with minimal side effects.12346

What data supports the effectiveness of the drug BBP-418 (Ribitol) for treating Limb-Girdle Muscular Dystrophy?

Research shows that ribitol can improve muscle function and increase lifespan in mouse models of Limb-Girdle Muscular Dystrophy by enhancing the expression of a protein called matriglycan, which is important for muscle health. Additionally, combining ribitol with gene therapy has shown promising results in improving muscle pathology in similar conditions.12345

Are You a Good Fit for This Trial?

This trial is for individuals aged 12-60 with genetically confirmed LGMD2I/R9, weighing over 30 kg. They must understand and consent to study procedures, use effective contraception if of childbearing or reproductive potential, and be able to complete all study tasks like biopsies. Exclusions include significant other diseases, severe kidney issues, recent surgeries affecting assessments, pregnancy/breastfeeding intentions within the study period through 12 weeks after last dose.

Inclusion Criteria

I have a genetic diagnosis of LGMD2I/R9 and show symptoms.
The participant (or parent/guardian) who signs the ICF understands the study procedures and agrees to participate in the study
I am willing to use effective birth control during the study.
See 2 more

Exclusion Criteria

Participants must not have a score of zero on any one or more of the primary or key secondary endpoints at the time of screening
I haven't used ribose or sugar alcohol supplements in the last 90 days.
Participants must not have active suicidal ideation
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BBP-418 or placebo for long-term administration

Long-term

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • BBP-418 (Ribitol)
Trial Overview The trial tests BBP-418 (Ribitol) for safety and effectiveness in treating Limb Girdle Muscular Dystrophy type 2I (LGMD2I). Participants will receive either the investigational drug or a placebo over a long-term period to see how well it works compared to not receiving the active treatment.
How Is the Trial Designed?
2Treatment groups
Active Control
Placebo Group
Group I: BBP-418Active Control2 Interventions
Group II: Placebo to Match BBP-418Placebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

ML Bio Solutions, Inc.

Lead Sponsor

Trials
3
Recruited
200+

Citations

Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model. [2023]
CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model. [2023]
Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I. [2023]
Cytidine Diphosphate-Ribitol Analysis for Diagnostics and Treatment Monitoring of Cytidine Diphosphate-l-Ribitol Pyrophosphorylase A Muscular Dystrophy. [2020]
ISPD Overexpression Enhances Ribitol-Induced Glycosylation of α-Dystroglycan in Dystrophic FKRP Mutant Mice. [2020]
Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security